ArticleBMC ophthalmology2026
Short-term outcomes of aflibercept biosimilar SB15 in macular edema secondary to retinal vein occlusion.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the short-term outcomes of SB15, an aflibercept biosimilar approved by the U.S. Food and Drug Administration, for the treatment of macular edema secondary to retinal vein occlusion (RVO).
methodsThis retrospective study included 29 treatment-naïve patients diagnosed with macular edema secondary to branch retinal vein occlusion (BRVO)(n = 24) or central retinal vein occlusion (CRVO) (n = 5). All patients received intravitreal SB15 injection as the initial treatment and were followed up for a mean of 7.1 months. Additional injections were administered as necessary. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were evaluated at baseline, after the first injection, and at the final follow-up in both the BRVO and CRVO groups.
resultsIn the BRVO group, the mean logMAR BCVA improved from 0.64 ± 0.36 at baseline to 0.45 ± 0.26 after the first injection and to 0.41 ± 0.32 at the final follow-up (P < 0.001). The mean CRT decreased from 527.1 ± 181.9 μm to 261.3 ± 95.8 μm and 285.1 ± 99.5 μm, respectively (P < 0.001). In the CRVO group, the mean logMAR BCVA improved from 1.29 ± 0.26 at baseline to 0.90 ± 0.54 after the first injection and to 0.78 ± 0.61 at the final follow-up (P = 0.022). The mean CRT decreased from 897.0 ± 344.5 μm to 213.2 ± 24.4 μm and 439.4 ± 268.9 μm, respectively (P = 0.015).
conclusionsSB15 demonstrated short-term anatomical and visual improvements in patients with RVO-associated macular edema, suggesting that it may have some therapeutic effect in this condition. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.